Thyrotoxicosis with pegylated interferon alfa-2b.
BACKGROUND: Despite adequate surgery, a diagnosis of stage III melanoma carries a high risk of relapse, and hence mortality. Interferon alfa is the only treatment that has currently been shown to alter the natural history of the disease, delaying relapse-free survival, particularly in patients with...
Main Authors: | Lowndes, SA, Asher, R, Middleton, MR |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
2010
|
Registos relacionados
-
Efficacy of pegylated interferon alfa-2b «Algeron» in the treatment of chronic hepatitis C
Por: M. V. Mayevskaya, et al.
Publicado em: (2013-03-01) -
Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C
Por: T Kanda, et al.
Publicado em: (2011-03-01) -
Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma
Por: Dong-Dong Jia, et al.
Publicado em: (2021-06-01) -
HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b
Por: Hui Ma, et al.
Publicado em: (2016-01-01) -
Effectiveness of add-on Pegylated interferon alfa-2a therapy in a Lamivudine-treated patient with chronic hepatitis B
Por: Mangano Carmelo, et al.
Publicado em: (2011-01-01)